Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer

Cancer Medicine(2020)10.1002/cam4.3583Source: DataRank Database

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer is a research paper published in Cancer Medicine (2020). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: goldTopics (26)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Zeeshan Fazal ORCID,Ratnakar Singh ORCID,Emmanuel Bikorimana ORCID,Nabil Adra ORCID,Nasser H. Hanna ORCID

Live enrichment

PubMed:33135391

National Institutes of Health

Grant: 5R01CA211875-05

DNA Methylation Inhibitor Therapy for Testicular Cancer

National Institutes of Health

Grant: 1R03CA223709-01A1

A Novel Clinically Relevant Tumor Suppressor in Human Breast Cancer

goldLicense: CC BY

https://doi.org/10.1002/cam4.3583

https://www.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3583

https://pubmed.ncbi.nlm.nih.gov/33135391

http://dx.doi.org/10.1002/cam4.3583

https://dx.doi.org/10.1002/cam4.3583

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

AdultMaleIndianaTime FactorsMaximum Tolerated DoseDNA methyltransferase610Young AdultTesticular cancerTesticular NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansDNA methylationDose-Response Relationship, DrugClinical Cancer ResearchGuadecitabineMiddle AgedNeoplasms, Germ Cell and EmbryonalTreatment OutcomeDrug Resistance, NeoplasmSGI-110AzacitidineEpigeneticsCisplatin

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy

10.6084/m9.figshare.14299486.v1figshare

Additional file 1 of Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy

10.6084/m9.figshare.14299486figshare